CC-223 + azacitidine

CC-223 + azacitidine is a combination therapy under investigation for cancer treatment, particularly in hematologic malignancies. CC-223 is an oral small molecule inhibitor targeting both mTORC1 and mTORC2 complexes, which are key regulators of cell growth, proliferation, and survival. By inhibiting both complexes, CC-223 can overcome feedback activation pathways that often lead to resistance with mTORC1-only inhibitors[6]. Azacitidine is a pyrimidine nucleoside analogue and demethylating agent that incorporates into DNA and RNA to disrupt nucleic acid metabolism and inhibit DNA methyltransferase activity. This results in hypomethylation of DNA and cytotoxicity to abnormal hematopoietic cells[4][3]. Azacitidine is approved for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)[4][2]. The combination aims to leverage the complementary mechanisms—epigenetic modulation by azacitidine with direct inhibition of oncogenic signaling by CC-223—to enhance anti-tumor efficacy.

Brand names

ONUREG

Other names

CC223CC-223CC 223Vidaza